OS Therapies Initiates US FDA BLA Filing for OST-HER2 in the Prevention or Delay of Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma

Request for FDA Rolling Review submitted to FDA on January 30, 2026Non-Clinical and CMC BLA modules submitted to FDAAt FDA's ...

OS Therapies Announces Positive Biomarker Data from Phase 2b Clinical Trial of OST-HER2

Activation of immune blood biomarkers from interferon gamma pathway distinguished long-term survivors (>=2 years) ...
Business Wire

OS Therapies Announces Phase 2b Clinical Trial of OST-HER2 Achieves Primary Endpoint with Statistical Significance in the Prevention of Recurrent, Fully Resected, Lung ...

NEW YORK--(BUSINESS WIRE)--OS Therapies, Inc. (NYSE-A: OSTX), a clinical-stage biotechnology company advancing immunotherapies and targeted drug conjugates for cancer treatment, today announced ...

OS Therapies Announces Filing Form S-1 of OS Animal Health Subsidiary

OS Animal Health (OSAH), a wholly owned OS Therapies (OSTX) subsidiary, targets an IPO on NYSE American or Nasdaq ...
Hosted on MSN

KPop Demon Hunters OST tops Billboard 200 for first time

The original soundtrack (OST) album for the Netflix animated film *KPop Demon Hunters, hereinafter referred to as KPop Demon Hunters* has topped the Billboard 200, the main album chart, for the first ...
Hosted on MSN

KPop Demon Hunters OST reclaims Billboard 200 top spot

The original soundtrack (OST) of the Netflix animated film *KPop Demon Hunters* (hereafter *KPop Demon Hunters*), which achieved global success by blending K-pop and Korean traditional culture, has ...